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The purpose of this research was to determine the potential of
papain and pequi oil as penetration enhancers for diclofenac
sodium (DS) across human skin in vitro. The permeation studies
were conducted with vertical diffusion cells. The enhancers were
associated or not in gels in different concentrations. In vitro studies
reveled that papain 0.2% (w/v) presented an elevated enhancer
property for diclofenac sodium (J = 0.3369 μg/cm2x h). Pequi oil
10% (w/v) generated a reduced flux value (J = 0.1848 μg/cm2x h)
and a combination of both enhancers presented a medium value
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The skin has been shown as a suitable delivery route
for drugs formulated in transdermal therapeutic systems
(TTS). Many strategies have been suggested in order to
overcome the low permeability of drugs through the skin.
One of them has been to include penetration enhancers in
formulations. These substances remove reversibly the
barrier resistance of the stratum corneum and permit the
access of the drug to the viable tissues and systemic
circulation (Barry, 2001). Different substances have been
used for this purpose, including terpens and oleic acid
(Escribano et al., 2003).
The aim of this research work was to determine the
potential of papain and pequi oil, as penetration enhancers
in the percutaneous absorption of drugs. Diclofenac sodium
(DS) has been used as model drug due to its hydrophilic
characteristic that is not easily absorbed upon transdermal
application (Nishihata et al., 1988; Escribano et al., 2003).
Papain (P) is a sulfhydryl protease from Carica papaya
latex. This proteolytic enzyme has been used in the
treatment of large skin lesions by its ability to remove
injured tissues and to stimulate the cicatrisation process.
Papain has been used before as a keratolytic substance to
improve the delivery of antimycotic drugs through human
nail (Quintanar-Guerreiro et al., 1998; Pinto et al., 2007).
Pequi oil (PO) is extracted from pequi, Caryocar
brasiliense a typical Brazilian fruit, which is rich in oleic
acid (about 50%), and it has been used in cosmetic
formulations as an emollient agent. However, the action as
penetration enhancer of the association of papain and pequi
oil has not been investigated yet.
On the other side, the current trend is a revival of the
interest in the use of natural products in pharmaceutical
products and dosage forms. The general public are using
natural raw materials or botanical extracts in many ways,
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such as conventional and complementary therapies, and
also the pharmaceutical industry, as a source of new lead
molecules for using as drug or as ingredients to
formulations. Therefore the natural products offer a vast,
virtually untapped reservoir of chemical compounds with
many potential uses (Rolim et al., 2006; Baby et al., 2007).
MATERIAL AND METHODS
Material
Henrifarma (Brazil) supplied diclofenac sodium
(99,9%). Pequi oil was obtained from Farma Service - Ion
Química (Brazil). Papain, 30 000 USP-U/mg, was
obtained from Merck (Germany). All the materials and
reagents were of pharmaceutical or analytical grade
without any further purification.
Membrane preparation
Human skin, obtained from breast reduction plastic
surgery with dermatome targeted to 500 micrometers was
supplied by Hospital of São Paulo, São Paulo, Brazil. Skins
samples were obtained from Afro-Brazilian and Caucasian
women aging from 20 to 48 years old. Samples were
immediately placed in Eagles Minimum Essential Medium
(MEM) with Earle’s Balanced Salt Solution (BSS) and
gentamicin 50 mg/mL ,supplied by Gibcobrl. The skin was
stored at 4.0 ± 0.5 °C in this medium during 24 hours . On
the day of the experiment, the skin was washed and
immediately used for the diffusion (permeation) studies. This
experiment was carried out under approval of Ethic
Committee of School of Pharmaceutical Sciences of
University of São Paulo (FCF-SP).
Gel Formulation
An aqueous gel formulation was used to evaluate the
enhancer properties of papain and pequi oil. DS was added
to an acrylic polymer hydrophilic gel (Carbopol® Ultrez
10). Pequi oil was tested at two different concentrations,
5% and 10%, and papain at 0.2% and 0.05%. In addition,
a combination of substances, pequi oil 7.5% and papain
0.1%, was tested (Table I).
Permeation Studies
The permeation studies were carried out on Franz-type
diffusion cells with a diffusion area of 1.651 cm2. Three
Franz cells were mounted in a Multistirrer - IUCHI system
and placed in a thermostatic bath at 37.0 + 0.5 ºC. The skin
membranes were first cleaned with MEM-BBS with
gentamicin, which also served as receptor fluid in the recep-
tor compartment. Approximately 0.5 g test gel was placed on
the donor side. At predetermined time intervals, 600 mL
samples were withdrawn from the receiver compartment and
an equal volume of fresh medium was replaced to maintain
constant volume. Diclofenac sodium was determined by
HPLC previously validated (Lopes et al., 2003).
HPLC analyses were undertaken using a Shimadzu
LC-10 AD equipped with three pumps, Detector-UV -VIS
- Shimadzu SPD -10A, Shimadzu Auto Injector –SIL- 10A
and software Class –LC10 (version 1.61). A reversed-
phase column (25 cm x 4.5 mm I.D.) packed with Econosil
C18 (5 mm) was used with precolumn Econosil C18
(7mm). Samples were injected in a volume of 15 mL and
detected at 283 nm. The mobile phase consisted of
methanol: acetic acid 3% v/v water solution (74:26) and
was run at 1mL/min. Various concentrations of DS in
MEM-BBS with gentamicin were used to construct the
standard curve, one for each experiment. All studies were
conducted using the infinite-dose technique and the
permeation data from the in vitro experiment was analyzed
using the lag time method. In addition, the experiments
were carried out for 56 h, requiring at least three lag times
to achieve a steady-state flux (Shah, 1993; Shah et al.,
1994). The parameters estimated using the lag time method
were the steady-state flux (J), permeability coefficient (P),
Lag Time (Tlag), diffusion coefficient (D) and skin/donor
phase partition coefficient (K).
TABLE I - Gel formulations.
Formulations Analyte-free 1 2 3 4 5
Carbopol® Ultrez 10 (w/w) (%) 0.5 0.5 0.5 0.5 0.5 0.5
Diclofenac sodium (w/w) (%) 1.5 1.5 1.5 1.5 1.5 1.5
Pequi oil (w/v) (%) - 5 10 - - 7.5
Papain (w/w) (%) - - - 0.2 0.05 0.1
Cystein (w/w) (%) - - - 0.04 0.01 0.02
Purified Water q. s. to (g) 100 100 100 100 100 100
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Statistical analysis
The statistical significance of the data (p < 0.05) was
computed with a one-way ANOVA, and the software used
was Statistica®.
RESULTS AND DISCUSSION
The reduction in side effects, improving patient
compliance, and avoiding hepatic first-pass metabolism are
some of the advantages of the transdermal therapeutic
systems. The ability of the drug to permeate the skin, in
particular the stratum corneum is mostly affected by the
chemical enhancers that may increase transdermal and
topical delivery (Barry, 2001).
The results corresponding to the parameters of
permeation were presented at Table II, as the average of each
duplicate experiment and the range of the considered values.
Possible differences in the mean level of response
produced by different treatments (formulation) or in the
TABLE II - Percutaneous penetration values of flux, permeability coefficient, Lag Time, Diffusion coefficient, Partition
Coefficient and type of skin used in fourteen experiments.
Formulation Volunteer J (μg/cm2xh) P (cm/h) Tlag (h)  D(cm2/h) K (x 10-6)
(Treatment) (age, race) (x 10-6) (x 10-3)
1 32, Afro Brazilian 0.2905 1.94 12.155 3.43 2.825
33, Caucasian 0.1627 1.08 9.229 4.51 1.201
30, Caucasian 0.2132 1.42 8.757 4.76 1.494
2 48, Afro Brazilian 0.1921 1.28 10.410 4.0 1.63
43, Afro Brazilian 0.1774 1.18 5.160 8.07 0.732
3 39, Caucasian 0.3904 2.6 5.707 7.3 1.783
21, Caucasian 0.3416 2.28 5.824 7.15 1.592
39, Caucasian 0.2786 1.86 4.828 8.63 1.076
4 20, Caucasian 0.2387 1.59 5.411 7.7 1.033
30, Caucasian 0.1478 0.985 6.851 6.08 0.81
24, Caucasian 0.2704 1.8 5.670 7.35 1.227
5 42, Caucasian 0.2364 1.58 6.336 6.58 1.198
25, Caucasian 0.2710 1.81 6.333 6.58 1.373
29, Afro Brazilian 0.1486 0.991 5.245 7.94 0.624
Flux (J); Permeation coefficient (P); Lag Time (Tlag); Diffusion coefficient (D); Partition Coefficient (K).
TABLE IV - Multiple range comparison procedure for flux by formulation (treatment) by Tukey test
Treatment {1} {2} {3} {4} {5}
(formulation) 0.2221333 0.1870500 0.3368667 0.2189667 0.2186667
1 {1} 0.527764 0.039809* 0.948605 0.943746
2 {2} 0.527764 0.020557* 0.564909 0.568504
3 {3} 0.039809* 0.020557* 0.035709* 0.035343
4 {4} 0.9348605 0.564909 0.035709* 0.995127
5 {5} 0.943746 0.568504 0.035343* 0.995127
*denotes a statistically significant difference.
TABLE III - ANOVA one-way for formulation (treatment)
and flux.
Sum of Degrees of Mean F-ratio Significance
squares freedom square level
Effect 0.037406 4 0.009351 2.731007 0.097025
Error 0.030818 9 0.003424
degree of variation of the data were determined by the
statistical analyses.
Tables III to VIII showed the one-way ANOVA for
the permeation parameters of flux, permeability and Lag
Time for all formulations (treatment). Tables III, V and VII
expressed the analyses of variance. The values described
for flux and permeation coefficient presented an important
significance level. It was not possible to obtain any
significant difference between lag time values. The Tables
IV, VI and VIII expressed the multiple range analysis for
permeation parameters by formulations (treatments).
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The statistical analysis of the flux (Figure 1) showed
that there was an important difference between the Papain
0.2% formulation and the other formulations. This could be
an indication that papain acted like a penetration enhancer
more effectively.
The permeation coefficient (Figure 2) confirmed that
papain 0.2% enhanced the permeation of DS through the
skin. The plot showed an increased in the mean values of
formulation 3, confirming enhancer characteristic of papain.
The Lag Time statistical analyses (Figure 3) showed
statistical differences between the Papain 0.2% and other
formulations, with pequi oil 5% having the greatest Lag
Time values. These data confirmed, once more, that
formulation containing papain 0.2% was the best enhancer
for the DS permeability.
As the lag time method was used, the precision of the
values of J and Lag Time when combined with the thickness
of the barrier resulted in significant errors in the estimation
of D and K. Thus, the parameters D and K are only
effective and realistic for use in observation of the
mechanism of diffusion or the structure of the membrane.
Therefore, a mass transfer coefficient such as the
permeability coefficient is more useful to the interpretation
of this phenomena (Shah, 1993).
TABLE V - Analysis of variance table for formulation (treatment) and permeability (cm2/h), one-way factorial design .
Sum of Degrees of Mean of F-ratio Significance
squares Freedom squares Level
Effect 1.668464 4 0.417113 2.732013 0.096948
Error 1.374094 9 0.152677
TABLE VII - Analysis of variance table for formulation (treatment) and Lag Time, one-way factorial design.
Sum of Degrees of Mean of F-ratio Significance
squares Freedom squares level
Effect 42.57146 4 10.64286 4.143432 0.035637
Error 23.11750 9 2.56861
TABLE VI - Multiple range analysis for permeability (cm2/h) by formulation (treatment), one-way factorial design.
Treatment {1} {2} {3} {4} {5}
(formulation) 1.480000 1.245000 2.246667 1.45833 1.460333
1 {1} 0.526501 0.039698* 0.947340 0.952194
2 {2} 0.526501 0.020437* 0.564529 0.560954
3 {3} 0.039698* 0.020437* 0.035513* 0.035880*
4 {4} 0.947340 0.564529 0.035513* 0.995135
5 {5} 0.952194 0.560954 0.035880* 0.995135
*denotes a statistically significant difference.
TABLE VIII - Multiple range analysis for Lag Time by formulation (treatment), one-way factorial design
Treatment {1} {2} {3} {4} {5}
(formulation) 10.04739 7.78327 5.453519 5.978027 5.9719656
1 {1} 0.156476 0.0066138* 0.012524* 0.012431*
2 {2} 0.156476 0.145445 0.247993 0.246526
3 {3} 0.006613* 0.145445 0.697902 0.701201
4 {4} 0.012524* 0.247993 0.697902 0.996400
5 {5} 0.012431* 0.246526 0.701201 0.996400
*denotes a statistically significant difference.
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The diffusion coefficient also indicated that papain
0.2% had the best results as an enhancer. Conversely, the
partition coefficient data did not show any statistical
difference between any of the formulations, a consistent
FIGURE 1 - Plot of means of Flux (μg/cm2h) in function of
treatments (formulations).
FIGURE 2 - Plot of means of permeability (cm2/h) in
function of treatments (formulations).
FIGURE 3 - Plot of means of Lag Time (h) in function of
treatments (formulations).
result with the above related facts.
The fluid receptor used was modified Earle’s medium
(MEM) with gentamicin 50 mg/mL, described elsewhere.
The MEM is a very rich medium, used for cell culture and
creates interference in HPLC analysis. In order to remove
this interference, in each experiment, a standard profile was
performed and R2 values between 0.9771 and 1 were
obtained (Lopes et al., 2003).
In 1989, Goodman and Barry suggested that an
effective penetration enhancer should interact with both
intercellular and transcellular corneum components. To
activate this situation we used a combination of enhancers,
papain 0.1% and pequi oil 7.5%, expected to act by
different mechanisms (Goodman, Barry, 1989).
The flux, permeability coefficient and Lag Time
profiles of this formulation demonstrated a behavior very
similar to that of papain 0.05%, probably indicating that
the enhancer concentrations were not optimized.
Finally, when the data from the pre-treatment (data
not shown) were observed, the partition coefficient values
were higher than those for the formulations. These facts
have been demonstrated in literature (Goodman, Barry,
1989) and may also suggest that the gel formulations
retained DS, blocking its penetration. This result is
corroborated by Özgüney and co-workers (2006) and
Escribano and co-workers (2003) that observed that DS
was easily released from microemulsions and liquid
formulations in comparison with gels.
Figure 4 reported the in vitro permeation profiles of
DS with papain and pequi oil through human skin. A linear
relationship was obtained when the total amount of DS /cm2
in the receptor phase was plotted against time, indicating that
the human skin is permeable to DS and that percutaneous
transport can be described by zero order kinetics.
FIGURE 4 - In vitro permeation profile of DS with two
different enhancers: ( ) papain 0.2%; ( ) pequi oil 5%.
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Diffusion profiles achieved using the Franz cell
indicate that papain 0.2% (w/v) was the best permeation
enhancer for diclofenac sodium across human skin (the data
obtained are presented in Table II).
Although pequi oil (PO) is rich in oleic acid (about
50%), it was not efficiently enough on DS permeation,
probably due to its low concentration in the formulation.
Adjust must be done to improve its enhancer effect, raising
final concentration or even changing the basic formulation.
Probably an emulsion could be more effective to delivery
when enriched with pequi oil and this component could also
act as an emollient agent.
CONCLUSIONS
The results of this research work showed that papain
could be a good candidate as a penetration enhancer to
delivery of drugs through the skin. Moreover, a combination
of pequi oil and papain presented better enhancer
performance than isolated pequi oil in the formulations
analyzed.
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RESUMO
Avaliação in vitro da papaína e do óleo de pequi como
promotores de permeação cutânea para diclofenaco
de sódio em pele humana
O objetivo desta pesquisa foi determinar in vitro o poten-
cial da papaína e do óleo de pequi como promotores de
penetração cutânea para o diclofenaco de sódio (DS)
através de pele humana. Os estudos de penetração foram
conduzidos em células de difusão vertical. Os promotores
foram associados ou não em géis em concentrações dis-
tintas. A avaliação in vitro revelou que a papaína 0,2% p/
p apresentou propriedade promotora maior para o
diclofenaco de sódio (J = 0,3369 μg/cm2x h). O óleo de
pequi 10,0% p/v promoveu redução do fluxo (J = 0,1848
μg/cm2x h) e a combinação de ambos os promotores apre-
sentou valor mediano de fluxo de J = 0,2187 μg/cm2x h.
A partir dos resultados,  verificou-se que a papaína exer-
ceu ação promotora de penetração cutânea melhor que o
óleo de pequi
UNITERMOS: Papaína/ avaliação in vitro. Óleo de
Pequi/ avaliação in vitro. Permeação cutânea in vitro/pro-
motores. Diclofenaco de sódio/penetração cutânea.
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